Cargando…
Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection
On December 22, 2021, the United States Food and Drug Administration approved the first main protease inhibitor, i.e., oral antiviral nirmatrelvir (PF-07321332)/ritonavir (Paxlovid), for the treatment of early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nirmatrelvir inhib...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Xi'an Jiaotong University
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628234/ https://www.ncbi.nlm.nih.gov/pubmed/36345404 http://dx.doi.org/10.1016/j.jpha.2022.10.005 |